VNRX · Volitionrx Ltd
$0.38
-0.02 (-4.52%)
At close · Sep 2
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company concluded that these plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$5.23M
Shares
13.65M
VNRX metrics
54 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.39
Market cap
$5.23M
Price action
19 metricsPrice change (1W)
+2.5%
Price change (30D)
-50.7%
Price change (3M)
-83.0%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
134.8%
Beta
—
RSI (14D)
30.2
Price vs SMA 50
-56.4%
Price vs SMA 200
—
Avg volume (3M)
7.41M
Relative volume
0.3
Average dollar volume
$3.76M
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
13.65M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
4.2×
reciprocal yield 23.7%
EV / EBITDA
—
EV / EBIT
—
P / sales
2.5×
reciprocal yield 40.1%
P / book
—
FCF yield
-319.3%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-417.2%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
52.7×
reciprocal yield 1.9%
EV / revenue historical average (5Y)
333.2×
reciprocal yield 0.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-14
Profitability
9 metricsGross margin
—
Operating margin
-790.2%
Trailing 12 months
Net margin
-1,041.0%
Gross profit (TTM)
—
Operating profit (TTM)
−$19.42M
Net income (TTM)
−$25.59M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-796.7%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-2.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.46M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+78.4%
Year over year · more shares
Revenue CAGR (3Y)
+78.0%
Revenue CAGR (5Y)
+164.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-308.2%
Debt / equity
—
Current ratio
0.3
EBITDA (TTM)
−$18.55M
Free cash flow (TTM)
−$19.58M
Quick ratio
0.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$4.25M
Latest balance sheet
Cash & equivalents
$2.80M
Total assets
$8.30M
Total debt
$7.05M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$19.56M
Capital expenditures (TTM)
$21,969
R&D (TTM)
$9.41M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
382.7%
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
24
13F filer change QoQ
-7
Institutional ownership
14.1%
Short interest
3 metricsShort interest
5.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
63 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged